Company news
Neurosense Therapeutics Ltd. (NASDAQ:NRSN) news
Neurosense Therapeutics Ltd. news releases on 6ix. Latest, Oct 2, 2026: NeuroSense Provides Update on Nasdaq Listing Compliance
Press releases & updates
NeuroSense Provides Update on Nasdaq Listing Compliance
October 2, 2026
NeuroSense Provides Update on Nasdaq Listing Compliance
October 1, 2026
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
September 28, 2026
NeuroSense Provides Business Update and Progress for the First Half of 2026
September 25, 2026
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
August 31, 2026
NeuroSense Issues CEO Letter to Shareholders
August 13, 2026
NeuroSense Advances PrimeC toward New Drug Submission to Health Canada for ALS
July 23, 2026
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
July 22, 2026
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
July 6, 2026
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
June 29, 2026
NeuroSense Therapeutics : Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
June 25, 2026
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
June 25, 2026
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
June 22, 2026
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
June 11, 2026
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
June 8, 2026
NeuroSense Announces Pricing of Insider-Led PIPE Financing
April 27, 2026
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
April 6, 2026
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
April 2, 2026
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
March 31, 2026
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
March 23, 2026
/C O R R E C T I O N -- NeuroSense/
March 17, 2026
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
March 15, 2026
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
March 8, 2026
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
February 18, 2026
NeuroSense Expands Global IP Protection Strategy with Granted Australian Patent Covering PrimeC Composition
February 10, 2026
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
February 9, 2026
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
January 21, 2026
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
January 8, 2026
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
December 22, 2025
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
December 4, 2025
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
November 24, 2025
NeuroSense to Host Investor Webinar on December 8, 2025
November 3, 2025
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
October 6, 2025
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
September 10, 2025
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
September 4, 2025
NeuroSense Provides Business Update and Progress for the First Half of 2025
July 30, 2025
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community
July 22, 2025
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
May 7, 2025
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
April 24, 2025
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment
April 9, 2025
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates
April 7, 2025
NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting
April 4, 2025
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug
March 20, 2025
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
January 5, 2025
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
December 22, 2024
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
December 17, 2024
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
December 10, 2024
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS
December 3, 2024
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
December 1, 2024